Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma

Introduction: Brentuximab vedotin (BV) is a monoclonal antibody that targets CD30 antigen. It is indicated for the treatment of CD30 + lynnphonnas and classical Hodgkin lymphoma (HL), including advanced (stage III-IV) untreated disease, relapsed/refractory disease, and consolidation after autologous hematopoietic stem cell transplantation. In clinical trials the incidence of a hypersensitivity reaction is 1.2%. Cases report: We present 3 cases of patients with refractory HL and anaphylaxis to the administration of BV (Table 1). Symptoms are analyzed using a grading system described by Brown (2004) and a desensitization protocol was performed with a total dose of 100 mg of BV in 4 solution bags with an initial concentration of 1:1000 of total dose for cases of severe anaphylaxis, and desensitization of 3 solution bags with baseline concentration of 1:100 for cases of moderate anaphylaxis. Management & Outcome: Intradermal skin tests were positive. Before desensitization, premedication with methylprednisolone and chlorphenamine was administered, as well as fluid therapy with 0.9% physiological solution at 100 cc/hour at induction stage, 250 cc/hour at maintenance stage, and increased to 500 cc/hour in case of hypersensitivity reaction. Discussion: Drug desensitization in 12 or 16 steps allows tolerable administration of brentuximab vedotin after moderate to severe anaphylaxis. The favorable response to treatment of these patients may indicate that desensitization is a viable strategy for patients with relapsed or refractory HL.

Automated summary

Brentuximab vedotin (BV) is a monoclonal antibody used for the treatment of CD30+ lymphomas and classical Hodgkin lymphoma (HL). This article presents three cases of refractory HL patients who experienced anaphylaxis to BV administration and discusses a desensitization protocol used for their treatment. The results suggest that desensitization may be a viable strategy for patients with relapsed or refractory HL.